

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>O I P E</i> MAR 17 2004 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <i>JCTOS</i> USE SEVERAL SHEETS IF NECESSARY	ATTY. DOCKET NO. MANNK.032A	APPLICATION NO. 10/657,022
	APPLICANT Simard, et al.	
	FILING DATE September 5, 2003	GROUP 1645

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>RS</i>	1.	5,683,886	11/04/97	van der Brugger, et al.			
	2.	5,342,774	03/30/94	Boon, et al.			
	3.	5,445,939	08/29/95	Anderson			
	4.	5,538,866	07/23/96	Israeli, et al.			
	5.	5,571,711	11/05/96	van der Bruggen, et al.			
	6.	5,610,013	03/11/97	Van den Eynde, et al.			
	7.	5,635,363	06/03/97	Altman, et al.			
	8.	5648226	07/15/97	Van den Eynde, et al.			
	9.	5,656,446	08/12/97	Anderson			
	10.	5,747,271	05/05/98	Boon-Falleur, et al.			
	11.	5,804,381	09/08/98	Chen, et al.			
	12.	5,830,753	11/03/98	Coulie, et al.			
	13.	5,830,755	11/03/98	Nishimura, et al.			
	14.	5,844,075	12/01/98	Kawakami, et al.			
	15.	5,856,136	01/05/99	Au-Young			
	16.	5,858,689	01/12/99	van der Bruggen, et al.			
	17.	5,935,818	08/10/99	Israeli, et al.			
	18.	5,993,828	11/30/99	Morton			
	19.	6,013,481	01/11/00	DeBacker, et al.			
	20.	6,015,884	01/18/00	Schneck, et al.			
	21.	6,025,191	02/15/00	Pfreundschuh			
<i>W</i>	22.	6,069,001	05/30/00	Van den Eynde, et al.			

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES	NO	
<i>RS</i>	23.	WO 97/41440	11/06/97	PGT WO	—	—	

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>116107</i>
'EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.'			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. MANNK.032A	APPLICATION NO. 10/657,022
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard, et al.	
		FILING DATE September 5, 2003	GROUP 1645



## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
				YES	NO		
WMS	24. WO 99/02183	01/21/99	PCT WO	—	—		
	25. WO 01/82963	11/08/01	PCT WO	—	—		
	26. WO 02/081646	10/17/02	PCT WO	—	—		
	27. WO 02/069907	02/12/02	PCT WO	—	—		
	28. WO 02/062368	08/15/02	PCT WO	—	—		
✓	29. WO 03/063770	08/07/03	PCT WO	—	✓		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
WMS	30. Aharoni, et al. "Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex." <i>Nature</i> . 351: 147-150, (1991).	
	31. Ambrosini, G. et al. "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma," [Abstract]. <i>Nat. Med.</i> 3: 917-921, (1997).	
	32. Andersen, et al. "A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells." <i>Proc. Natl. Acad. Sci. USA</i> . 93: 1820-1824, (1996).	
	33. Borsi, L. et al. "Differential Expression of the Fibronectin Isoform Containing the ED-B Oncofetal Domain in Normal Human Fibroblast Cell Lines Originating from Different Tissues." <i>Exp. Cell Res.</i> 199: 98-105, (1992).	
	34. Carnemolla, B. et al. "A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors." <i>J. Cell Biol.</i> 108: 1139-1148, (1989).	
	35. Castellani, P. et al. "The Angiogenesis Marker ED-B+ Fibronectin Isoform in Intracranial Meningiomas." <i>Acta Neurochir. (Wien)</i> 142: 277-282, (2000).	
	36. Castellani, P. et al. "The Fibronectin Isoform Containing the ED-B Oncofetal Domain: A Marker of Angiogenesis." <i>Int. J. Cancer</i> 59: 612-618, (1994).	
	37. Cebon, et al. "Phase I Studies of Immunization with Melan-A and IL-12 in HLA A2+ Positive Patients with Stage III and IV Malignant Melanoma," [Abstract 1680], American Society of Clinical Oncology 35 <sup>th</sup> annual Meeting, Atlanta (1999).	
	38. Chaux, et al. "Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by <i>In Vitro</i> with Dendritic Cells Transduced with MAGE-A1," <i>J. Immunol.</i> 163(5): 2928-2936 (1999).	
	39. Chen, et al. "Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1." <i>J. Immunol.</i> 165: 948-955, (2000).	
	40. Chevalier. "Increased Expression of the Ed-B-Containing Fibronectin (An Embryonic Isoform of Fibronectin) in Human Osteoarthritic Cartilage." <i>Br. J. Rheumatol.</i> 35: 407-415, (1996).	
	41. Chung et al. "Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-Cell Epitopes in Hepatitis B Virus X Antigen." <i>J. Immunother.</i> 22: 279-287, (1999).	
✓	42. Chung, D. H., et al. "NK and CTL Recognition of a Single chain H-2D Molecule: Distinct Sites of H-2D Interact with NK and TCR." <i>J. Immunol.</i> 163: 3699-3708, (1999).	


EXAMINER	DATE CONSIDERED
11/6/03	
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.032A	APPLICATION NO. 10/657,022
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(USE SEVERAL SHEETS IF NECESSARY)</i>		
APPLICANT Simard, et al.		
FILING DATE September 5, 2003		GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
(Listed only)	43. "Measurement of MHC/Peptide Interactions by Gel Filtration." <i>Current Protocols in Immunology</i> , John Wiley and Sons, New York, 18.3.1-18.3.19, (1998).	<i>NO Copy</i>
M S	44. Dadaglio, et al. "Characterization and Quantitation of Peptide-MHC Complexes Produced from Hen Egg Lysozyme Using a Monoclonal Antibody." <i>Immunity</i> . 6: 727-738, (1997).	
	45. Dela Cruz, et al. "Creating HIV-1 reverse transcriptase cytotoxic T lymphocyte target structures by HLA-A2 heavy chain modifications. <i>Int. Immunol.</i> 12:1293-1302, (2000).	
	46. Di Fiore, et al. "erbB-2 is a Potent Oncogene When Overexpressed in NIH/3T3 Cells." <i>Science</i> . 237: 178-182, (1987).	
	47. Dietrich, et al. "Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes." <i>Nat. Biotech.</i> 16: 181-185, (1998).	
	48. Duc, et al. "Monoclonal antibodies directed against T cell epitopes presented by class I MHC antigens." <i>Int. Immunol.</i> 5: 427-431, (1993).	
	49. Eastman, et al. "A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody." <i>Eur. J. Immunol.</i> 26: 385-393, (1996).	
	50. Engberg, et al. "Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy." <i>Immunotechnology</i> . 4: 273-278, (1999).	
	51. Farnoud, M.R. et al. "Fibronectin Isoforms are Differentially Expressed in Normal and Adenomatous Human Anterior Pituitaries." <i>Int. J. Cancer</i> . 61: 27-34, (1995).	
	52. Franco, et al. "Epitope affinity for MHC class I determines helper requirement for CTL priming." <i>Nature Immunol.</i> 1(2): 145-150, (2002).	
	53. Gabler, U. et al. "Matrix remodeling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants." <i>Heart</i> . 75: 358-362, (1996).	
	54. Gold and Freedman. "Demonstration of Tumor-Specific Antigens in Human Colonic Carcinoma by Immunological Tolerance and Absorption Techniques." <i>J. Exp. Med.</i> 121: 439-462, (1965). Fuller references can be found in the Online Mendelian Inheritance in Man; record #114890.	
	55. Gure, A.O. et al. "SSX: A Multigene Family with Several Members Transcribed in Normal Testis and Human Cancer." <i>Int. J. Cancer</i> . 72: 965-971, (1997).	
	56. Kaczmarek, et al. "Distribution of Oncofetal Fibronectin Isoforms in Normal, Hyperplastic and Neoplastic Human Breast Tissues." <i>Int. J. Cancer</i> . 59: 11-16, (1994).	
	57. Kalergis, et al. "Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMCH complex." <i>Nature Immunol.</i> 2: 229-234, (2001).	
	58. Karelina, T.V. and A.Z. "Interstitial Collagenase and the ED-B Oncofetal Domain of Fibronectin Are Markers of Angiogenesis in Human Skin Tumors." <i>Cancer Detect. Prev.</i> 22: 438-444, (1998).	
	59. Lebowitz, M.S. et al. "Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes: Biochemical Probes for Analysis and Modulation of Immune Responses." <i>Cell Immunol.</i> 192: 175-184, (1999).	
	60. Lee, et al. "Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active $\beta_2$ -microglobulin domain." <i>Eur. J. Immunol.</i> 24: 2633, (1994).	
	61. Lordon-Rosa, et al. "Distribution of Oncofetal Fibronectin in Human Mammary Tumors: Immunofluorescence Study on Histological Sections." <i>Cancer Res.</i> 50: 1608-1612, (1990).	
	62. Madden. "The Three-Dimensional Structure of Peptide-MHC Complexes." <i>Annu. Rev. Immunol.</i> 13: 587-622, (1995).	

EXAMINER	DATE CONSIDERED	116/07
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.032A	APPLICATION NO. 10/657,022
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Simard, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE September 5, 2003	GROUP 1645



EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
<i>MS</i>		63. Mage, et al. "A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity." <i>Proc. Natl. Acad. Sci. USA.</i> 89: 10658, (1992).	
		64. Mandel, et al. "Oncofetal fibronectins in oral carcinomas: Correlation of two different types." <i>APMIS.</i> 102: 695-702, (1994).	
		65. Matsuura, H. and S. Hakomori. "The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma." <i>Proc. Natl. Acad. Sci. USA.</i> 82: 6517-6521, (1985).	
		66. Midulla. "Source of Oncofetal ED-B-containing Fibronectin: Implications of Production by Both Tumor and Endothelial Cells." <i>Cancer Res.</i> 60: 164-169, (2000).	
		67. Mottez, et al. "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic." <i>J. Exp. Med.</i> 181: 493, (1995).	
		68. Neri, et al. "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform." <i>Nat. Biotech.</i> 15:1271-1275, (1997).	
		69. Nicolo, et al. "Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer." <i>Cell Differ. Dev.</i> 32: 401-408, (1990).	
		70. Oehen, et al. "Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA." <i>Immunology.</i> 99, 163-169, (2000).	
		71. Oyama, F. et al. "Coordinate Oncodevelopmental Modulation of Alternative Splicing of Fibronectin Pre-Messenger RNA at ED-A, ED-B, and CS1 Regions in Human Liver Tumors1." <i>Cancer Res.</i> 53: 2005-2011, (1993).	
		72. Parker, et al. "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains." <i>J. Immunol.</i> 152: 163, (1994).	
		73. Plaksin, D. et al. "A Three-Domain T Cell Receptor Is Biologically Active and Specifically Stains Cell Surface MHC/Peptide Complexes 1,2." <i>J. Immunol.</i> 158: 2218-2227, (1997).	
		74. Polakova, K., et al. "Antibodies Directed Against the MHC-1 Molecule H-2Dd Complexed with an Antigenic Peptide: Similarities to a T Cell Receptor with the Same Specificity1." <i>J. Immunol.</i> 165: 342-348, (2000).	
		75. Porgdor, et al. "Localization, Quantitation, and In Situ Detection of Specific Peptide-MHC Class I Complexes Using a Monoclonal Antibody." <i>Immunity.</i> 6: 715-726, (1997).	
		76. Pujuguet, P. et al. "Expression of Fibronectin ED-A+and ED-B+ Isoforms by Human and Experimental Colorectal Cancer." <i>Am. J. Pathol.</i> 148: 579-592, (1996).	
		77. Puri, et al. "Modulation of the Immune Response in Multiple Sclerosis." <i>J. Immunol.</i> 158: 2471-2476, (1997).	
		78. Salgaller et al. "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Peripheral Blood Lymphocytes Stimulated in Vitro with Synthetic Peptides." <i>Cancer Res.</i> 55: 4972-4979, (1995).	
		79. Scheinberg, et al. "BCR-ABL Breakpoint Derived Oncogene Fusion Peptide Vaccines Generate Specific Immune Responses in Patients with Chronic Myelogenous Leukemia (CML)." [Abstract 1665], American Society of Clinical Oncology 35 <sup>th</sup> Annual Meeting, Atlanta (1999).	
		80. Serwold, et al. "ER aminopeptidases generate a unique pool of peptides for MHC class I molecules." <i>Nature Immunol.</i> 2: 644-651, (2001).	
		81. Slamon, et al., "Use of Chemotherapy Plus a Monoclonal Antibody Against Her2 for Metastatic Breast Cancer that Overexpresses Her2." <i>New Eng. J. Med.</i> 344: 783-792, (2001). A more detailed description is available in the Online Mendelian Inheritance in Man; record #164870	
		82. Stauss et al. "Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-cell Epitopes in Human Papilloma Virus." <i>Proc. Natl. Acad. Sci. USA.</i> 89: 7871-7875, (1992).	

EXAMINER	DATE CONSIDERED	<i>11/6/07</i>
----------	-----------------	----------------


\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  MAR 7 2004 RENT-A-TRADEMAKERSOURCE JC105	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  USE SEVERAL SHEETS IF NECESSARY	ATTY. DOCKET NO. MANNK.032A	APPLICATION NO. 10/657,022
		APPLICANT Simard, et al.	
		FILING DATE September 5, 2003	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
115	83. Tarli, L. et al. "A High-Affinity Human Antibody That Targets Tumoral Blood Vessels." <i>Blood</i> . 94: 192-198, (1999).
	84. Toshitani, K., et al. "Expression of a single-chain HLA class I molecule in a human cell line: Presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes." <i>Proc. Natl. Acad. Sci. USA</i> . 93: 236, (1996).
	85. Tsai, et al. "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells." <i>J. Immunol.</i> 158: 1796-1802, (1997).
	86. Tureci, O., et al. "Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens." <i>Proc. Natl. Acad. Sci. USA</i> . 95: 5211-5216, (1998).
	87. Uger, R. A. and B. H. Barber. "Creating CTL Targets with Epitope-Linked $\beta_2$ -Microglobulin Constructs1." <i>J. Immunol.</i> 160: 1598, (1998).
	88. Uger, R. A., et al. "Covalent Linkage to $\beta_2$ -Microglobulin Enhances the MHC Stability and Antigenicity of Suboptimal CTL Epitopes1." <i>J. Immunol.</i> 162: 6024, (1999).
	89. Van de Vijver, et al. "Association with Comedo-type Ductal Carcinoma in Situ and Limited Prognostic Value in Stage II Breast Cancer." <i>New Eng. J. Med.</i> 319: 1239-1245, (1988).
	90. Van den Eynde, B., et al. "Differential Processing of Class-1-Restricted Epitopes by the Standard Proteasome and the Immunoproteasome." <i>J. Exp. Med.</i> 182: 689-698, (1995).
	91. Velculiscu V.E. et al. "Analysis of human transcriptomes." <i>Nat. Genet.</i> 23: 387-388, (1999).
	92. Vose, J.M. "Tumor Antigens Recognized by T Lymphocytes," 10 <sup>th</sup> European Cancer Conference, Day 2, Sept 14, (1999).
	93. White, J., et al. "Soluble Class I MHC with $\beta_2$ -Microglobulin Covalently Linked Peptides: Specific Binding to a T Cell Hybridoma1." <i>J. Immunol.</i> 162: 2671, (1999).
✓	94. Yee, C. et al. "In vivo tracking of tumor-specific T cells." <i>Current Opinion in Immunology</i> . 13: 141-146, (2001).
✓	95. Yu, Y.L.Y., et al. "Cutting Edge: Single-Chain Trimmers of MHC Class I Molecules Form Stable Structures That Potently Stimulate Antigen-Specific T Cells and B Cells1." <i>J. Immunol.</i> 168: 3145-3149, (2002).

S:\DOCS\MTMMTM-5775.DOC  
022604.sma

EXAMINER	DATE CONSIDERED	116107
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		



FORM PTO 2449 APR 16 2004 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MANNK.032A	APPLICATION NO. 10/657,022
		APPLICANT Simard, et al.	
		FILING DATE September 5, 2003	GROUP 1645


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
W	1	6,037,135	03/2000	Kubo, et al.	—	—	

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
W	2	WO 94/020127	09/1994	W.I.P.O. (PCT) WO	—	—	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
W	3	International Search Report re International Appln. No. PCT/US03/27706; International Filing Date: 09/05/03. Applicant: MannKind Corporation; Date of Mailing of ISR: March 31, 2004.

S:\DOCS\MTMM\MTM-6000.DOC  
041204.dmr

EXAMINER	W	DATE CONSIDERED	11/10/07
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			



**SHEET 1 OF 1**

<p>FORM PTO-1449 AUG 30 2004 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	<p>ATTY. DOCKET NO. MANNK.032A</p>	<p>APPLICATION NO. 10/657,022</p>
<p>APPLICANT Simard et al.</p>		
<p>FILING DATE September 5, 2003</p>		<p>GROUP Unknown</p>

## **U.S. PATENT DOCUMENTS**


## **FOREIGN PATENT DOCUMENTS**

**EXAMINER  
INITIAL**

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

S:\DOCS\MTM\MTM-6405.DOC  
062204

EXAMINER		DATE CONSIDERED	1/6/07
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>			



~~NOV 13 2006~~

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(Multiple sheets used when necessary)*

SHEET 1 OF 1

PTO/SB/08 Equivalent

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
NJS	1	Longmate et al., "Population Coverage by HLA Class-I Restricted Cytotoxic T-lymphocyte Epitopes," <i>Immunogenetics</i> 52:165-173 (2001), XP-002216921	
WBL	2	2006-10-06 Communication with Supplementary Search Report in European Patent Application No. 03751997.2	

3084645 110306

Examiner Signature  Date Considered 11/6/07

**\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached